Market Overview

Sarah Cannon Research Institute to Present at ASCO Gastrointestinal Cancers Symposium

Share:
NASHVILLE, Tenn.--(BUSINESS WIRE)--

Sarah Cannon Research Institute (SCRI) physicians authored four abstracts accepted for presentation at the ASCO 2012 Gastrointestinal Cancers Symposium, which runs from Jan. 19-21 in San Francisco, CA.

“The incorporation of new agents, particularly targeted therapies, in the treatment of gastrointestinal cancers continues to improve clinical outcomes for patients,” said Howard A. Burris III, M.D., SCRI's chief medical officer and executive director, drug development. “We are honored to share results of this important research with the top GI cancer researchers in the world.”

Johanna Bendell, M.D., SCRI's director of gastrointestinal (GI) research and associate director of drug development and Jeffrey Infante, M.D., SCRI's director of drug development will present the findings of the following studies:

  • Phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer – author: Dr. Bendell, General Poster Session B, Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract, January 20, 11:45am-1:45pm PT
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors – author: Dr. Bendell, General Poster Session C, Cancers of the Colon and Rectum, January 21, 12:30-2:30pm PT
  • Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study – author: Dr. Bendell, General Poster Session C, Cancers of the Colon and Rectum, January 21, 12:30-2:30pm PT
  • Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumors—A focus on GI malignancies – lead author: Dr. Infante, General Poster Session B, Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract, January 20, 11:45am-1:45pm PT

About the 2011 Gastrointestinal Cancers Symposium

The annual Gastrointestinal (GI) Cancers Symposium is a three-day multidisciplinary meeting that offers the newest strategies in prevention, screening and treatment of gastrointestinal cancers. This multidisciplinary symposium offers educational sessions and abstract presentations focused on each type of GI cancer including cancers of the esophagus, stomach, hepatobiliary tract, pancreas, small bowel, colon and rectum. Co-sponsors of the Symposium include the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Surgical Oncology.

About SCRI

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit www.sarahcannonresearch.com.

Sarah Cannon Research Institute (SCRI)
Anna Walker, 615-329-7216
Anna.walker@scresearch.net

View Comments and Join the Discussion!